An open-label, Phase 1b study to evaluate the safety and tolerability of eflornithine plus temozolomide in patients with newly diagnosed glioblastoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Orbus Therapeutics, Inc.
Start Date
January 11, 2024
End Date
January 31, 2028
Administered By
Duke Cancer Institute
Awarded By
Orbus Therapeutics, Inc.
Start Date
January 11, 2024
End Date
January 31, 2028